Cas:129492-58-6 (2S)-3-hydroxy-2-phenylmethoxypropanal manufacturer & supplier

Chemical Name:(2S)-3-hydroxy-2-phenylmethoxypropanal

CAS.NO:129492-58-6

Synonyms:2-O-Benzylgylcerinaldehyd

Molecular Formula:C₁₀H₁₂O₃

Molecular Weight:180.20000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:46.53000

Exact Mass:180.07900

LogP:0.76300

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-O-Benzylgylcerinaldehyd chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-O-Benzylgylcerinaldehyd physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-O-Benzylgylcerinaldehyd Use and application,2-O-Benzylgylcerinaldehyd technical grade,usp/ep/jp grade.

Related News: Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. (2S)-3-hydroxy-2-phenylmethoxypropanal manufacturer To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early. (2S)-3-hydroxy-2-phenylmethoxypropanal supplier We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. (2S)-3-hydroxy-2-phenylmethoxypropanal vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). (2S)-3-hydroxy-2-phenylmethoxypropanal factory To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early.